Skip to main content
MRNA
NASDAQ Life Sciences

欧洲药品管理局药品人类使用委员会通过了对mCOMBRIAX的肯定意见，建议授予莫德纳的mRNA联合疫苗针对流感和COVID-19的营销授权

feedReported by Acceswire
Sentiment info
Positive
Importance info
8
Price
$51.7
Mkt Cap
$20.422B
52W Low
$22.28
52W High
$55.2
Market data snapshot near publication time

summarizeSummary

欧洲药品管理局药品人类使用委员会（CHMP）已经发出了一份肯定意见，建议授予莫德纳的mCOMBRIAX营销授权，这是一种针对流感和COVID-19的联合疫苗。这标志着一个重要的监管里程碑，因为mCOMBRIAX是世界上第一个获得此类建议的流感加COVID联合疫苗。这种积极的发展是在莫德纳最近提交的10-K文件（2月20日）之后发生的，该文件强调了收入的显著下降和其CMV疫苗的管道挫折。欧洲委员会的最终批准将为莫德纳在欧盟引入新的、可能很大的收入来源，多元化其产品组合，并解决大型市场的联合呼吸道病毒保护问题。投资者现在应该关注欧洲委员会关于营销授权的最终决定和随后的国家监管和准入程序。

在该公告发布时，MRNA的交易价格为$51.70，交易所为NASDAQ，所属行业为Life Sciences，市值约为$204.2亿。 52周交易区间为$22.28至$55.20。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Acceswire。

show_chartPrice Chart

Share this article

Copied!

feed MRNA - Latest Insights

MRNA
Apr 21, 2026, 9:40 AM EDT
Source: Access Newswire
Importance Score:
8
Moderna's mCOMBRIAX, World's First Flu-COVID Combo Vaccine, Gets EU Marketing Authorization
Sentiment: Positive
View Wiseek Article
MRNA
Mar 13, 2026, 6:58 AM EDT
Source: Reuters
Importance Score:
8
GSK's RSV Vaccine Gains Key FDA Approval for Younger Adults, Intensifying Competition for Moderna
Sentiment: Negative
View Wiseek Article
MRNA
Mar 04, 2026, 8:20 PM EST
Filing Type: 8-K
Importance Score:
8
Moderna Settles Patent Litigation for Up to $2.25B, Securing Royalty-Free Rights for Key Vaccines
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 04, 2026, 10:10 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Moderna Settles Major Covid-19 Vaccine Patent Suit for $2.25 Billion, Shares Rise
Sentiment: Positive
View Wiseek Article
MRNA
Mar 03, 2026, 4:28 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Moderna to Appeal to Federal Circuit Court, Citing Government-Contractor Immunity Defense
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 4:25 PM EST
Source: Reuters
Importance Score:
8
Moderna Projects $4.5B-$5B Year-End Cash, Reveals $950M Q1 Settlement Charge
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
8
Moderna's Cancer Vaccine Shows Reduced Recurrence, FDA Reverses Flu Vaccine Review
Sentiment: Positive
View Wiseek Article
MRNA
Feb 27, 2026, 7:00 AM EST
Source: Acceswire
Importance Score:
8
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Sentiment: Positive
View Wiseek Article
MRNA
Feb 20, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
8
Moderna Reports $2.8B Net Loss in 2025 Amidst 40% Revenue Decline, Discontinues CMV Vaccine in Congenital CMV
Sentiment: Negative
View Wiseek Article
MRNA
Feb 13, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
7
Moderna Reports Q4 & FY25 Results, Projects 10% Revenue Growth in 2026, Faces US Flu Vaccine Setback
Sentiment: Neutral
View Wiseek Article